Transformed into Dogwood Therapeutics (NASDAQ:DWTX) in Dec 2024
VIRI - Virios Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Alpharetta,
United States
Type: Equity
VIRI price evolution
VIRI
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.02 | $2.38 | $3.32 | $4.79 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $3.64 | $3.22 | $4.17 | $5.25 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $3.64 | $3.22 | $4.17 | $5.25 |
| Current liabilities | ||||
| Accounts payable | $0.22 | $0.2 | $0.11 | $0.21 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $0.5 | $0.57 | $0.36 | $0.49 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $0.5 | $0.57 | $0.36 | $0.49 |
| Shareholders' equity | ||||
| Retained earnings | -$63.81 | -$62.76 | -$61.47 | -$60.37 |
| Other shareholder equity | ||||
| Total shareholder equity | $3.14 | $2.65 | $3.81 | $4.76 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.32 | $7.03 | $14.01 | $29.8 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $4.17 | $8.37 | $15.78 | $31.47 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $4.17 | $8.37 | $15.78 | $31.47 |
| Current liabilities | ||||
| Accounts payable | $0.11 | $0.57 | $0.35 | $0.37 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $0.36 | $1.04 | $1.28 | $1.53 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $0.36 | $1.04 | $1.28 | $1.53 |
| Shareholders' equity | ||||
| Retained earnings | -$61.47 | -$56.17 | -$43.93 | -$27.97 |
| Other shareholder equity | ||||
| Total shareholder equity | $3.81 | $7.33 | $14.5 | $29.94 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.34 | $0.34 | $0.3 | |
| Selling, general & administrative | $0.73 | $0.97 | $0.84 | |
| Total operating expenses | $1.07 | $1.31 | $1.14 | |
| Operating income | -$1.07 | -$1.31 | -$1.14 | |
| Income from continuing operations | ||||
| EBIT | -$1.05 | -$1.29 | -$1.1 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$1.05 | -$1.29 | -$1.1 | |
| Income (for common shares) | -$1.05 | -$1.29 | -$1.1 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $1.73 | $8.07 | $10.8 | $0.19 |
| Selling, general & administrative | $3.72 | $4.25 | $4.85 | $9.81 |
| Total operating expenses | $5.45 | $12.32 | $15.64 | $10.01 |
| Operating income | -$5.45 | -$12.32 | -$15.64 | -$10.01 |
| Income from continuing operations | ||||
| EBIT | -$5.3 | -$12.25 | -$15.97 | -$9.96 |
| Income tax expense | ||||
| Interest expense | -$0.01 | $0.38 | ||
| Net income | ||||
| Net income | -$5.3 | -$12.25 | -$15.96 | -$10.35 |
| Income (for common shares) | -$5.3 | -$12.25 | -$15.96 | -$10.35 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$1.05 | -$1.29 | -$1.1 | -$1.24 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.15 | $0.14 | $0.15 | $0.15 |
| Total cash flows from operations | -$0.81 | -$0.94 | -$1.47 | -$0.96 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.16 | |||
| Net borrowings | ||||
| Total cash flows from financing | $1.16 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.64 | -$0.94 | -$1.47 | $0.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$5.3 | -$12.25 | -$15.96 | -$10.35 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.62 | $0.58 | $0.32 | $7.43 |
| Total cash flows from operations | -$4.87 | -$11.47 | -$15.69 | -$3.9 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.16 | $4.49 | -$0.1 | $31.53 |
| Net borrowings | $1.93 | |||
| Total cash flows from financing | $1.16 | $4.49 | -$0.1 | $33.38 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.71 | -$6.98 | -$15.79 | $29.49 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 27.76M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 0.11 |
| Cash/Share | 0.11 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.09 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.27 |
| Quick ratio | 7.27 |